XTX Topco Ltd Buys 64,981 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

XTX Topco Ltd grew its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 167.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 103,716 shares of the biopharmaceutical company’s stock after purchasing an additional 64,981 shares during the quarter. XTX Topco Ltd’s holdings in Sangamo Therapeutics were worth $90,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of SGMO. Renaissance Technologies LLC raised its stake in Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock worth $1,479,000 after buying an additional 1,528,600 shares in the last quarter. Marshall Wace LLP raised its position in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 207,476 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $89,000. Finally, Vontobel Holding Ltd. boosted its position in shares of Sangamo Therapeutics by 412.3% during the third quarter. Vontobel Holding Ltd. now owns 300,000 shares of the biopharmaceutical company’s stock valued at $259,000 after purchasing an additional 241,440 shares in the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SGMO has been the subject of several recent research reports. Barclays raised their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. StockNews.com upgraded shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Sangamo Therapeutics in a report on Thursday. Finally, Truist Financial upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research note on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock opened at $2.47 on Friday. The company has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $1.13. The stock has a market capitalization of $515.36 million, a PE ratio of -3.29 and a beta of 1.15. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. The company had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same period in the previous year, the business earned ($0.34) EPS. As a group, equities research analysts forecast that Sangamo Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.